Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
Allegra
C J
CJ
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology; D042943:Dihydrouracil Dehydrogenase (NADP); D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis* / Q000517:prevention & control; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000378:metabolism*; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology*; D010088:Oxidoreductases / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology
D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil